Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2008 Oct;59(10):1121-30.
doi: 10.1176/ps.2008.59.10.1121.

Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants

Richard Hansen  1 , Bradley Gaynes, Patricia Thieda, Gerald Gartlehner, Angela Deveaugh-Geiss, Erin Krebs, Kathleen Lohr
Affiliations
Meta-Analysis

Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants

Richard Hansen et al. Psychiatr Serv. 2008 Oct.

Abstract

Objective: This meta-analysis reviewed data on the efficacy and effectiveness of second-generation antidepressants for preventing major depression relapse and recurrence during continuation and maintenance phases of treatment, respectively.

Methods: MEDLINE, EMBASE, and PsycINFO, the Cochrane Library, and International Pharmaceutical Abstracts were searched for the period of January 1980 through April 2007 for reviews, randomized controlled trials, meta-analyses, and observational studies on the topic. Two persons independently reviewed abstracts and full-text articles using a structured data abstraction form to ensure consistency in appraisal and data extraction.

Results: Four comparative trials and 23 placebo-controlled trials that addressed relapse or recurrence prevention were included. Results of comparative trials have not demonstrated statistically significant differences between duloxetine and paroxetine, fluoxetine and sertraline, fluvoxamine and sertraline, and trazodone and venlafaxine. Pooled data for the class of second-generation antidepressants compared with placebo suggested a relatively large effect size that persists over time. For preventing both relapse and recurrence, the number of patients needed to treat is five (95% confidence interval of 4 to 6). Differences in the length of open-label treatment before randomization, drug type, and trial duration did not affect pooled estimates of relapse rates. Across all trials, 7% of patients randomly assigned to receive active treatment and 5% of patients randomly assigned to receive a placebo discontinued treatment because of adverse events.

Conclusions: This review demonstrates the overall benefits of continuation- and maintenance-phase treatment of major depression with second-generation antidepressants and emphasizes the need for additional studies of comparative differences among drugs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Meta-analysis of placebo-controlled trials with less than 1 year of double-blinded randomized followup for relapse or recurrence prevention
Figure 2
Figure 2
Meta-analysis of placebo-controlled trials with 1 year or more of double-blinded randomized followup for relapse or recurrence prevention
Figure 3
Figure 3
Weighted mean relapse frequency by length of followup P= 0.59 for test of difference in relapse rates for drug versus placebo over time
See this image and copyright information in PMC

References

    1. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Annals of Internal Medicine. 2005;143:415–426. - PubMed
    1. Practice guideline for the treatment of patients with major depressive disorder (revision) American Psychiatric Association. American Journal of Psychiatry. 2000;157:1–45. - PubMed
    1. Depression guideline panel. Depression in primary care: Volume 2, Treatment of major depression. AHCPR publication No. 93-0550. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993.
    1. Loonen AJ, Peer PG, Zwanikken GJ. Continuation and maintenance therapy with antidepressive agents. Meta-analysis of research. Pharmaceutisch Weekblad Scientific Edition. 1991;13:167–175. - PubMed
    1. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653–661. - PubMed

Publication types

MeSH terms

Substances